University of Pennsylvania, Perelman School of Medicine University of Pennsylvania, Perelman School of Medicine Gulph Mills, Pennsylvania, United States
Session Description: As the US continues to address the addiction crisis, the treatment field and the public have increasingly viewed addiction as a chronic medical illness, however, our approach to treatment delivery and measurement have not reflected this. The Institute of Medicine has called for greater development, implementation, and measurement of evidence-based practices (EBPs) but ensuring adequate adherence and competence in clinical delivery of these practices has lagged. Here we look at the development, delivery, and measurement of EPBs in addiction treatment. We examine the role of stigma, evidence that addiction is a chronic illness, and results of clinically based research on treatment available for substance use disorders. We look how to measure “success” in treatment from the perspective of the insurer, buyer, seller, patient, family, and research community. We provide an argument against the most commonly used measure of success – “total abstinence” as the sole or most important measure in the field and discuss how that came about and the damage it does to the field. Treatment providers who want to survive and thrive will have to deliver evidence-based practices along a full continuum of care and show accountability through data aggregation, transparency, and outcomes.
Learning Objectives:
After this activity participants should be able to
Upon Completion, treatment center leadership/staff will be able to identify various “evidence-based practices” and where to obtain publicly available resources for these practices
Upon Completion, participants will be able to describe potential tools, instruments and curriculum that can be used for EBP and MBC in the behavioral health field.
Upon Completion, executives, buyers, evaluators, and counselors will be able to identify best predictors for selecting substance abuse treatment programs.